Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
about
The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decisionUrokinase receptor and resistance to targeted anticancer agentsEpithelial-mesenchymal plasticity in carcinoma metastasisHypoxia-inducible factor 1 and breast cancer metastasisThe Regulatory Role of MicroRNAs in EMT and CanceruPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism.Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cellsThe phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling.DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype.Establishment of Hertwig's epithelial root sheath/epithelial rests of Malassez cell line from human periodontium.Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathwayCell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cellsPhosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.TGF-β signaling in breast cancer cell invasion and bone metastasis.In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancerComprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cellsGlobal liver gene expression differences in Nelore steers with divergent residual feed intake phenotypesImaging active urokinase plasminogen activator in prostate cancer.Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.Plectin as a prognostic marker in non-metastatic oral squamous cell carcinomaGenome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancerSimultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes.HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancerA novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroA distinct role for interleukin-6 as a major mediator of cellular adjustment to an altered culture condition.The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease.Role of urokinase receptor in tumor progression and development.The relevance of the TGF-β Paradox to EMT-MET programsPalmitoylated claudin7 captured in glycolipid-enriched membrane microdomains promotes metastasis via associated transmembrane and cytosolic molecules.Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistanceFOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator systemDirect repression of MYB by ZEB1 suppresses proliferation and epithelial gene expression during epithelial-to-mesenchymal transition of breast cancer cells.Luteolin reduces the invasive potential of malignant melanoma cells by targeting β3 integrin and the epithelial-mesenchymal transition.
P2860
Q26775618-703DEC15-A09A-439F-916A-091276E5F3FFQ26797385-6E2FA5F0-3395-4709-A964-3448A4C5D66FQ26859804-DBFCDA85-4244-43D3-A1F6-F1CBA8F06067Q28087393-AED8F6FD-189E-4FAC-8575-425932E2567FQ28391426-C4FBE36B-CD7F-4473-AF13-B3D79C1E29E9Q30249137-F2245A1C-7079-41E4-B2D9-FC9167451F22Q30361219-59F3F816-98F7-48AF-A786-D6ADE7F9633FQ33709060-2734F110-2FFF-4936-BA52-092E3C68745FQ33887570-DE4EE97F-A0B6-4BE4-8B8C-619006C4BC33Q33953134-BA70F014-7EB6-49BF-B467-98CCDF33F30BQ33995723-3725F6B1-1ADD-4B7A-9007-1E30DD4EFFF2Q34025989-137D6605-9446-421F-B333-33A612C94F46Q34042660-2B694350-FC7C-4A38-BB78-A5C14B6A301BQ34043029-7D2AB996-F003-4085-A42D-F6559F5A26D1Q34048106-624F4E45-A311-4542-96FA-E86E69CC9A0CQ34267846-C5ABDC50-89A8-4A3A-8CE2-D3176C6A82A9Q34899974-B7F465D7-7CC0-41A5-89E3-F991FA4E5755Q34985004-9ECE0914-F321-4582-84FF-C598B96A4BACQ34997475-84560A3E-DBD0-4C52-8569-6B0287CD255DQ35032720-79CE2DA3-0F3F-4BA0-8E8F-22C89D347460Q35238125-3D4B3575-FF2D-4CAC-84CC-171F0C052CA2Q35251858-5D7C7C56-36C1-4534-A5F9-D8B50C216CA9Q35604600-0AA4CAC6-1C60-4611-AB69-242815DF7C7AQ35610049-086C8B0F-C710-4DEA-A380-9CA386AA9B70Q35755113-CD3F9BC3-39B2-4D1D-AD35-69B0CEA5A08EQ36201682-ECAC1107-1526-42EC-8FBB-8B7E1675DE76Q36610815-2BFAA19F-A5FE-4825-9EAF-5D51F690FE06Q36670686-71214EC6-C27A-4E85-9726-03B755091A52Q36745487-F694CE76-7276-4036-9414-A96723AA88CFQ36791190-0FC27747-EF40-4B58-ABBE-7841C1452E2BQ36799733-A94BEDC6-4911-4A6A-9BEE-80DC52A0C69DQ36980771-F21735CD-6A20-424F-8F3E-D334B2A38F4CQ36997616-DC7CF0D8-4FD2-4B4A-91E0-46CBC8C4AFC3Q37118399-911133A6-8C55-45B8-B185-B5D32DBAC6A0Q37327571-23514351-27A3-40ED-A245-F8AC77A489EDQ37536780-234EE1DF-152A-4B71-9DAA-E3DDA4EE6078Q37558869-6F8CB1B4-6142-4AB9-98DF-A47736FCF323Q37646911-BD1761B7-85D8-4590-B1E1-72E8AC27BC57Q37690963-9649C465-B132-429E-A369-550E739AEF0CQ37728714-DDF0063E-2E6E-4C10-81A9-F24408F29A29
P2860
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reversibility of epithelial-me ...... ptor-dependent cell signaling.
@en
Reversibility of epithelial-mesenchymal transition
@nl
type
label
Reversibility of epithelial-me ...... ptor-dependent cell signaling.
@en
Reversibility of epithelial-mesenchymal transition
@nl
prefLabel
Reversibility of epithelial-me ...... ptor-dependent cell signaling.
@en
Reversibility of epithelial-mesenchymal transition
@nl
P2093
P2860
P356
P1476
Reversibility of epithelial-me ...... ptor-dependent cell signaling.
@en
P2093
Boryana Eastman
Robin D Lester
Shinako Takimoto
Steven L Gonias
Valerie Montel
P2860
P304
22825-22833
P356
10.1074/JBC.M109.023960
P407
P577
2009-06-22T00:00:00Z